Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Institutes of Health Clinical Center
GOALS of Liver Disease Effects Lecture -Estimation of Hepatic Clearance - Effect of Liver Disease on Elimination: - RESTRICTIVELY Eliminated Drugs - NON-RESTRICTIVELY Eliminated Drugs - Other Effects of Liver Disease: - Renal Function - Drug Distribution - Drug Response - Modification of Drug Therapy in Patients with Liver Disease 2
Correlation of Lab Test Results with Impaired CYP Enzyme Function The Central Problem There is no laboratory test of liver function that is as useful for guiding drug dose adjustment in patients with liver disease as is the estimation of creatinine clearance in patients with impaired renal function. 3
FDA Approved Drug Labels Dosing Guidance in Liver Disease Evaluation of hepatic impairment dosing recommendation in FDA approved product labels. 4
ADDITIVITY of Clearances Equation showing that total elimination clearance equals the sum of renal and nonrenal clearances 5
CALCULATION OF CL H Equation showing that hepatic clearance is estimated as the total clearance minus the renal clearance, assuming that it equals non-renal clearance. 6
FICK EQUATION Defines clearance as liver blood flow times the extraction ratio A-V/A. 7
Derivation of Rowland Equation (I) Diagram of hepatic capillary blood flow, fraction of unbound drug and intrinsic clearance with the well-stirred model. 8
Derivation of Rowland Equation (II) The same diagram now including volume and concentration terms and a mass balance equation for hepatic drug clearance. 9
Derivation of Rowland Equation (III) The same diagram with a derivation of an extraction ratio term that includes unbound fraction, intrinsic clearance, and liver blood flow. 10
Rowland Equation WELL-STIRRED COMPARTMENT Rowland Equation for hepatic clearance. Two limiting cases: Restrictively metabolized drugs (influenced by protein binding) Non-restrictively metabolized drugs (blood flow-dependent) 11
RESTRICTIVELY AND NON-RESTRICTIVELY ELIMINATED DRUGS RESTRICTIVELY METABOLIZED DRUGS: Phenytoin Warfarin Theophylline NON-RESTRICTIVELY METABOLIZED DRUGS: Lidocaine Propranolol Morphine 12
HEPATIC FIRST-PASS METABOLISM Equation for the extraction ratio A-V/A. Illustration of hepatic first-pass metabolism and the portal and systemic circulations. 13
NON-RESTRICTIVELY Eliminated Drugs These drugs have extensive first-pass metabolism. Equation showing that hepatic clearance is a function of liver blood flow. 14
ACUTE VIRAL HEPATITIS - Acute inflammatory condition - Mild and transient changes related to extent of disease in most cases. Infrequently severe and fulminant -May become chronic and severe - Changes in drug disposition less than in chronic disease - Hepatic elimination returns to normal as disease resolves 15
CHRONIC LIVER DISEASE - Usually related to chronic alcohol use or viral hepatitis - Irreversible hepatocyte damage Decrease in SERUM ALBUMIN concentration Decrease in INTRINSIC CLEARANCE of drugs Intrahepatic and extrahepatic shunting of blood from functioning hepatocytes FIBROSIS disrupts normal hepatic architecture NODULES of regenerated hepatocytes form 16
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation showing that hepatic clearance equals unbound fraction times the intrinsic clearance. Chart showing that hepatic clearance increases if albumin decreases, and decreases if intrinsic clearance decreases. 17
RESTRICTIVELY METABOLIZED DRUGS: EFFECT OF PROTEIN BINDING CHANGES Equations showing that free drug concentration at steady-state is a function of dosing rate and intrinsic hepatic clearance. 18
FREE and TOTAL PHENYTOIN Levels (DOSE = 300 MG/DAY) Chart showing that total Phenytoin concentration is lower than normal in functionally anephric patients but free Phenytoin concentration is the same. 19
RESTRICTIVELY METABOLIZED DRUGS: EFFECT OF PROTEIN BINDING CHANGES Chart showing a protein binding interaction with Warfarin. There is a transient increase in free Warfarin concentration and prothrombin time. 20
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation showing that hepatic clearance equals unbound fraction times the intrinsic clearance. Chart showing that hepatic clearance increases if albumin decreases, and decreases if intrinsic clearance decreases. 21
ROLE OF CYP ENZYMES IN HEPATIC DRUG METABOLISM Pie chart showing relative hepatic content of CYP enzymes and pie chart showing % of drugs metabolized by CYP enzymes. 22
RESTRICTIVELY METABOLIZED DRUGS: EFFECT OF CIRRHOSIS ON Clint Chart illustrating % of normal intrinsic clearance for normal, mild, moderate, and severe cirrhosis, and the impact on glucuronidation and CYP2D6, CY3A4, CYP2C19, and CYP1A2. 23
PUGH-CHILD CLASSIFICATION OF LIVER DISEASE SEVERITY Chart showing assessment parameters and assigned scores in addition to classification of clinical severity of mild, moderate and severe. 24
CORRELATION OF SPECIAL TESTS OF LIVER FUNCTION WITH CHILD-PUGH SCORES* Chart showing changes in indocyanine green and sorbitol clearances, and the galactose elimination and the antipyrine breath tests. * Data from Herold C, et al. Liver 2001;21:260-5. 25
PITTSBURGH COCKTAIL APPROACH DRUG CAFFEINE CHLORZOXAZONE DAPSONE DEBRISOQUIN MEPHENYTOIN ENZYME CYP 1A2 CYP 2E1 CYP 3A + NAT2 CYP 2D6 CYP 2C19 * From: Frye RF, et al. Clin Pharmacol Ther 1997;62:365-76 26
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation showing that hepatic blood flow equals unbound fraction times the intrinsic clearance. Chart showing that hepatic clearance increases if albumin decreases, and decreases if intrinsic clearance decreases. Portosystemic shunting reduces total hepatic clearance and increases free drug concentration. 27
EFFECTS OF HEPATIC SHUNTING ON ROWLAND EQUATION* Modified Rowland Equation accounting for shunt blood flow. * From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6. 28
RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF HEPATIC SHUNTING* Chart showing liver disease severity, QT, QP, QP/QT, and Antipyrine CLH *From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6. 29
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation for hepatic clearance = blood flow showing that changes in protein binding and intrinsic clearance have no impact on hepatic clearance for these drugs. Chart * However, note that free concentration is 30
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation for CLH =Q Equation for hepatic clearance = blood flow showing that changes in protein binding and intrinsic clearance have no impact on hepatic clearance for these drugs. HOWEVER, fuclint MAY NO LONGER BE >> Q 31
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF LIVER DISEASE Equation for CLH = Q Equation for hepatic clearance = blood flow showing that changes in protein binding and intrinsic clearance have no impact on hepatic clearance for these drugs. Decreased hepatic perfusion results in increased oral bioavailability (F). 32
EFFECTS OF HEPATIC SHUNTING ON ROWLAND EQUATION* Modified Rowland Equation * From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6. 33
NON-RESTRICTIVELY METABOLIZED DRUGS: EFFECTS OF DECREASED LIVER PERFUSION* Chart showing liver disease Severity, QT, QP, QP/QT, and ICG CLH (clearance of indocyanine green) * From: McLean A, et al. Clin Pharmacol Ther 1979;25:161-6. 34
INFLUENCE OF PORTOSYSTEMIC SHUNTING ON ORAL BIOAVAILABILITY (f) RESTRICTIVELY Eliminated Drugs: Little change NON-RESTRICTIVELY Eliminated Drugs: SHUNTING may markedly increase oral bioavailability due to reduced first pass metabolism drug bypasses hepatocytes 35
CIRRHOSIS AFFECTS EXPOSURE TO SOME NON-RESTRICTIVELY METABOLIZED DRUGS Chart showing increased Absolute Bioavailability and relative exposure cirrhotics/control of Meperidine, Pentazocine, and Propranolol. * THIS ALSO INCORPORATES 55% INCREASE IN PROPRANOLOL fu 36
CIRRHOSIS AFFECTS RENAL FUNCTION: THE HEPATORENAL SYNDROME -Risk in Patients with Cirrhosis, Ascitis, and GFR > 50 ml/min: - 18% within 1 year - 39% within 5 years - Predictors of Risk: - Small liver - Low serum albumin - High plasma renin - Cockcroft and Gault Equation may overestimate renal function 37
CIRRHOSIS AFFECTS RENAL FUNCTION: THE HEPATORENAL SYNDROME - The Syndrome has a FUNCTIONAL rather than an Anatomical Basis. 38
HEPATORENAL SYNDROME ANTEMORTEM ARTERIOGRAM There is no renal perfusion. 39
Renal perfusion appears normal. HEPATORENAL SYNDROME POSTMORTEM Arteriogram 40
CIRRHOSIS AFFECTS RENAL FUNCTION: THE HEPATORENAL SYNDROME - Therapy with some drugs may precipitate Hepatorenal Syndrome ACE Inhibitors NSAIDs Furosemide (High Total Doses) 41
CIRROSIS MAY AFFECT DRUG DISTRIBUTION - Increased Free Concentration of NON-RESTRICTIVELY Eliminated Drugs (e.g. PROPRANOLOL) - Increased Permeability of Blood:CNS Barrier (e.g. CIMETIDINE) 42
CIRRHOSIS AFFECTS DRUG DISTRIBUTION: INCREASED CNS PENETRATION OF CIMETIDINE* Chart showing cimetidine CSF/serum ratio from normal to renal + liver disease to liver disease * From Schentag JJ, et al. Clin Pharmacol Ther 1981;29:737-43 43
CIRRHOSIS MAY AFFECT PHARMACODYNAMICS - Sedative response to BENZODIAZEPINES is exaggerated - Response to LOOP DIURETICS is reduced 44
Drugs CONTRAINDICATED in Patients with Severe Liver Disease - May precipitate renal failure: - NSAIDs - ACE Inhibitors - Predispose to bleeding: - β-lactams with N-Methylthiotetrazole Side Chain (e.g. CEFOTETAN) 45
Drug Requiring 50% Dose Reduction in Patients with MODERATE CIRRHOSIS ANALGESIC DRUGS CHANGE IN CIRRHOSIS F CLE Morphine 213% 59% Meperidine 94% 46% Pentazocine 318% 50% 46
Drugs Requiring 50% Dose Reduction in Patients with MODERATE CIRRHOSIS CHANGE IN CIRRHOSIS F CLE CARDIOVASC. DRUGS Propafenone 257% 24% Verapamil 136% 51% Nifedipine 78% 60% Losartan 100% 50% 47
Drugs Requiring 50% Dose Reduction in Patients with MODERATE CIRRHOSIS CHANGE IN CIRRHOSIS F CLE OTHER DRUGS Omeprazole 75% 89% Tacrolimus 33% 72% 48
PUGH-CHILD CLASSIFICATION OF LIVER DISEASE SEVERITY Chart showing assessment parameters with assigned score and classification of clinical severity of mild, moderate and severe. 49
RECOMMENDED EVALUATION OF PHARMACOKINETICS IN LIVER DISEASE PATIENTS* REDUCED Study Design: - Study Control Patients and Patients with Child-Pugh - Moderate Impairment - - Findings in Moderate Category Applied to Mild - Category; Dosing Prohibited in Severe Category FULL Study Design: - Study Control Patients and Patients in All Child-Pugh Categories - Population PK Approach * FDA Clinical Pharmacology Guidance, May 2003 50